Drugs / FB418
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05995782 | Dec 2023 → Dec 2024 overdue | Parkinson disease, amyotrophic lateral sclerosis | 1ST Biotherapeutics, Inc. | Recruiting | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-12-18 | 1ST Biotherapeutics, Inc. | 퍼스트바이오, 퇴행성뇌질환 신약후보 ‘FB418’ 국가신약개발사업 선정 1stbio.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FB418 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05995782 ↗ |
| Route | Oral | “Oral dose” NCT05995782 ↗ |